PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026Radiotherapy and Oncology2 citationsOpen Access

Integrating biomarker-derived individual treatment response assessment into Bayesian trial design for personalized cancer treatment

PKPavlos KoliasAAAli AjdariACA. Cicchetti

Key Points

  • Evaluate the integration of biomarker-derived treatment response assessments into Bayesian trial designs for cancer therapy.
  • Utilized Bayesian trial design for incorporating biomarkers into treatment plans.
  • Conducted simulations to identify intermediate responders for dose escalation.
  • Compared biomarker stratification efficacy with conventional trial designs.
  • Identified intermediate responders as optimal for dose escalation.
  • Poor and strong responders demonstrated limited benefits due to increased toxicity risks.
  • Stratification was feasible with about 100 patients, showing advantages over traditional methods.

Abstract

Our Bayesian trial design integrates biomarkers into RT dose adaptation Simulations identify intermediate responders as optimal candidates for escalation Poor and strong responders show limited net benefit due to toxicity risk Biomarker stratification feasible with ~100 patients vs conventional trials

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kolias et al. (2026) studied this question.

synapsesocial.com/papers/69b64c67b42794e3e660dbfbhttps://doi.org/10.1016/j.radonc.2026.111484
Ask AI
Helpful
Bookmark
Share
View Full Paper